Carbon-ion trials remain concentrated in few centers and mostly early-phase

Only 36 carbon-ion studies were open to enrollment worldwide, with most early-phase and 21 concentrated at three centers.

KEY POINTS

  • This PTCOG-sanctioned, expert-verified review identified 36 carbon-ion radiotherapy studies open to enrollment: 35 interventional trials and one registry-based comparative-effectiveness study. Trial registries were searched from December 2025 through February 2026 and findings were verified directly with participating centers.
  • The portfolio remained predominantly early-phase: 7 phase I, 23 phase II, 5 phase III, and 1 registry study. Most trials were single-arm, single-institution studies, or both.
  • Clinical activity was geographically concentrated. Japan had the largest portfolio, followed by Germany, China, Italy, Austria, and France, while the North American PROSPER registry provided a comparative-effectiveness platform. QST, SPHIC, and HIT together accounted for 21 of the 36 studies.
  • Pancreatic cancer and sarcoma-related tumors led the field with 7 studies each, followed by head and neck cancers with five and prostate and breast cancers with three each. Glioblastoma, lung, gynecologic, kidney, esophageal, hepatocellular, mucosal melanoma, and mixed-solid-tumor studies were less common.
  • Comparative evidence remains limited despite substantial institutional experience. The authors highlight randomized or multinational platforms such as ETOILE, SACRO, and PROSPER as particularly important because most active studies still focus on feasibility, safety, and single-center disease control.
  • Biological dose reporting remains a major barrier to cross-study interpretation. The review emphasizes that differences between LEM and MKM RBE models, as well as LET-related planning, require explicit reporting of physical dose, RBE-weighted dose, planning system, biological model, target coverage, and toxicity.
  • The authors propose a six-domain minimum reporting framework covering trial design, clinical context, endpoints, prescription and target coverage, OAR constraints, and biological modeling. Notably, the active inventory contained no pediatric studies.

CLINICAL TAKEAWAY

The current bottleneck in carbon-ion therapy is not simply a shortage of studies but a shortage of coordinated comparative evidence. PTCOG argues that multicenter accrual, harmonized endpoints, transparent RBE reporting, and prospective quality assurance may do more for the field than additional isolated single-institution series.

SOURCE

International Journal of Particle Therapy

Browse more research Suggest a correction